BB Biotech

Historical price data

Founded in 1993, BB Biotech AG is one of Europe's oldest and most established listed biotech investment firms, with a mission to advance human health through disciplined, long-term capital allocation. The company operates as a permanent capital vehicle, enabling it to take significant, active positions in publicly listed biotech companies with late-stage clinical assets or recently launched products, free from short-term redemption pressures. Its strategy centers on rigorous fundamental analysis of scientific pipelines and commercial potential, aiming to achieve capital appreciation by investing in innovation that addresses significant unmet medical needs.

A proprietary investment analysis and portfolio management platform that integrates deep scientific due diligence, probability-adjusted financial modeling, and active ownership strategies to identify and manage risk-adjusted exposure to biopharmaceutical innovation.

BB Biotech competes with other listed biotech funds, active healthcare mutual/hedge funds, and passive biotech ETFs. Its key differentiators are its permanent capital base enabling pure long-term focus, its three-decade track record of specialized investing, and its active, high-conviction portfolio management approach, which contrasts with the diversification of passive products.